SGD PHARMA

At CPhI WW 2019, SGD Pharma will be launching the first application to identify non-compliances in molded glass bottles intended for the pharmaceutical industry

Resulting from a development project between SGD Pharma Quality and Marketing departments, this new digital tool makes it possible to identify non-compliances that may be discovered during an incoming inspection or during on-line inspection at client’s side. The SGD Pharma App is a testament to our commitment to continuous improvement. It also demonstrates transparency in working with customers toward the mutual objective of safeguarding patient health.

The SGD Pharma group and its shareholder JIC, announce an investment of more than 20 million euros to rebuild the furnace and modernize the century-old Sucy-en-Brie site

The Sucy-en-Brie factory, 400 employees, has been dedicated to producing pharmaceutical bottles since 1917. The factory supplies syrups, droppers, tablets, injectable and infusion bottles to over 450 customers around the world and cover the following therapeutic areas: oral and parenteral antibiotics, parenteral nutrition, respiratory illness, pain-relievers, anesthetics, and OTC. Every year, 80,000 tons of Type II & III flint and amber molded glass bottles are produced there, making this factory one of the biggest players in the European health care industry. Its 41,000 m² surface includes ISO 8 clean rooms, two furnaces, and 8 production lines. The factory is ISO 15378 & 50001 certified.

Michel Giannuzzi elected Vice-President of the European Container Glass Federation (FEVE) and Laurent Zuber appointed as Chairman of the FEVE Glass Flaconnage Board

Michel Giannuzzi, Chairman and Chief Executive Officer of the Verallia Group – one of Europe’s leading glass packaging manufacturers for the food and beverage sector - has been elected Vice-President of FEVE – the European Container Glass Federation - at its FEVE General Meeting in Rotterdam on June 15th.

SGD Pharma introduces Clareo, its new premium range of molded glass vials in Type II, for injectable solutions.

Clareo vials from SGD Pharma offer a combination of homogeneous wall thickness and superior cosmetic quality, which for molded glass Type II is unique in the market. The new range offers technical characteristics similar to the vials in the existing range and can replace them without any regulatory change. Once again, SGD Pharma demonstrates with Clareo its expertise in the control of manufacturing process of molded glass.

Join the 155,000+ IMP followers